BBR treatment can elevate plasma GLP-1 and orexin-a, and upregulate hypothalamic GLP-1 receptor expression, which has beneficial effects on various metabolic disorders such as insulin resistance and obesity, thereby inducing regulation of the gut-brain axis of the microbiota (106). This evidence concerns the gene GLP1R and obesity disorder.